Skip to main content

Philips expands open patient monitoring ecosystem to help health systems keep sight of patients beyond the bedside

Female patient receiving care in hospital

Female patient receiving care in hospital
Female patient receiving care in hospital

Female patient leaving hospital

Female patient leaving hospital
Female patient leaving hospital

August 6, 2026

New collaborations expand wearable and out-of-hospital monitoring capabilities, helping support continuous patient visibility from admission through recovery at home 

Amsterdam, Netherlands. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare, further expanding its open monitoring ecosystem. The collaborations help health systems improve continuity and coordination of care by integrating wearable and out-of-hospital technologies into the Philips ecosystem, supporting connected patient monitoring from hospital to home. 

Driving the shift from episodic to longitudinal care
As healthcare systems expand higher-acuity services beyond traditional hospital settings, maintaining visibility into patient status across the care continuum becomes increasingly important. 

Philips is helping lead this shift through an interoperable monitoring ecosystem that gives health systems greater flexibility to deploy and scale monitoring programs using the technologies that best fit their clinical and operational needs. By connecting patient data across care settings, Philips is transforming data into actionable care intelligence, supporting more efficient care coordination throughout the patient’s journey.

“Monitoring is no longer just about what happens at the bedside. Healthcare organizations need a more connected approach that helps clinicians maintain visibility into patient status across care settings,” said Sangdo Kim, Category Leader, NextGen Acute and Transitional Care Monitoring, Philips. “By building an open, enterprise-wide ecosystem that connects technologies, data and workflows, we can help deliver continuous patient insight, support smoother transitions in care, and create a more coordinated experience for clinicians and patients.”

Building a connected monitoring ecosystem to support transitional care
The partnerships expand the range of continuous patient measurements that can be integrated into Philips ecosystem, such as the Patient Information Center (PIC) iX. The partnerships include the following products*:

  • Blue Spark Technologies – TempTraq wearable disposable patch supporting continuous core body temperature monitoring, clinically proven [1] to detect fevers earlier to enable improved patient visibility and early intervention, both inpatient and outpatient.
  • Caretaker Medical – VitalStream wearable solution supporting continuous non-invasive blood pressure and advanced hemodynamic monitoring to help enhance inpatient surveillance and clinical decision-making.
  • Cuviva – a core Hospital at Home platform technology partner, delivering a secure, advanced and fully integrated IT platform that enables structured, scalable hospital-at-home care through digital monitoring, real-time communication, and smooth integration with the Philips clinical workflows as well as hospitals’ digital infrastructure.
  • LifeSignals – UbiqVue Multiparameter Biosensor, a single-use, wireless, wearable, chest-based device supporting continuous, near real-time monitoring of 2-channel ECG, SpO₂, pulse rate, respiration rate, body temperature, posture and motion. Coupled with centralized software, it enables alert-driven, scalable, active patient monitoring across hospital and out-of-hospital settings.
  • Respiree – 1Bio(TM) platform + 1Bio(TM)AI + RS001 wearable biosensor technology enabling continuous cardio-respiratory monitoring, including patented direct respiratory rate and other lung physiological markers, pulse, SpO2, posture, and activity, helping support earlier identification of patient deterioration across care settings.
  • smartQare – viQtor & Healthdot wearable biosensor technologies supporting continuous monitoring of pulse, respiration, SpO2, skin temperature, and activity to help clinicians maintain visibility into patient status across care transitions.

Together, these capabilities complement Philips’ broader connected care portfolio which includes solutions designed to support monitoring beyond discharge. Philips Mobile Cardiac Telemetry (MCOT)* [2] enables clinicians to remotely monitor appropriate cardiac patients for up to 30 days following an inpatient or ED evaluation, supporting smoother transitions into the appropriate care pathway.

By combining enterprise monitoring capabilities with an open network of innovation partners, Philips is helping shape the future of continuous patient monitoring across the care continuum. Learn more about Philips HPM Technology Partnerships.

*Not all products are available in all markets.

[1] Lin C, Chen M, Chai J, et al. Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies [Abstract]. Blood. American Society of Hematology Annual Meeting; 2025:1075.
[2] Philips Mobile Cardiac Telemetry (MCOT) includes the MCOT device with SmartDetect algorithm. MCOT supports MCOT and Cardiac Event services, which include an end of service report, technician ECG review, and urgent/emergent notification of detected cardiac events when appropriate. The MCOT system is contraindicated for patients with potentially life-threatening arrhythmias requiring inpatient monitoring, and patients the attending physician recommends should be hospitalized for ECG monitoring. However, it can be utilized by professionals for monitoring cardiac patients at home after discharge.

For further information, please contact:

Allison Johnson
Business Communication Director
Tel: +1 617 631 7305
E-mail: Allison.Johnson@philips.com  

Anna Hogrebe
Philips Global External Relations
Tel.: +1 416 270 6757
E-mail: Anna.Hogrebe@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.